Delaram Mirzania, None;
Atalie Thompson, None;
Eduardo Mariottoni, None;
Leonardo Shigueoka, None;
Kelly Muir, AbbVie (S), AbbVie (F), Arbutus Biopharma (S), Axovant (S), Blade (S), Cymabay (F), Dova (S), Dova (F), Gilead Sciences,, Inc. (S), Gilead Sciences, Inc. (F), Graybug vision (S), Merck Sharpe & Dohme (F), Merck Sharpe & Dohme (Merck & Co, USA) (S), NGM Biopharmaceuticals (F), Precision Bioscience (S), ProQR (S), Shionogi Pharma (S), Shire Pharmaceuticals (S), Taiwan J Pharmaceuticals (F);
Felipe Medeiros, Aeri Pharmaceuticals (C), Allergan (C), Annexon (C), Biogen (C), Biozeus (C), Carl-Zeiss Meditec (F), Carl-Zeiss Meditec (C), Galimedix (C), Google (F), Heidelberg Engineering (F), IDx (C), NGoggle, Inc. (P), Novartis (C), Reichert (F), Reichert (C), Stealth Biotherapeutics (C)